Compare Abeona Therapeutics Inc (ABEO) vs Paycom Software Inc (PAYC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Paycom Software Inc — how do they compare? Abeona Therapeutics Inc trades at $6.69 (market cap $373.32M), while Paycom Software Inc trades at $139 (market cap $6.70B). The key difference: Paycom Software Inc is far larger — about 17.9× Abeona Therapeutics Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PAYC | |
|---|---|---|
Market Cap | $373.32M | $6.70B |
Sector | Health | Technology |
52-Week High | $7.23 | $238.80 |
52-Week Low | $4.17 | $113.59 |
Enterprise Value | $228.22M | $7.31B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Paycom Software (PAYC) trades at $143.78, up 3.28% on the day, with a bullish technical signal and strong fundamentals including a 22.44% net income margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $678.9 million in 2025. Analyst consensus is mixed with a $151 price target, while recent news highlights its value stock appeal and industry awards.
The outlook for PAYC is positive with solid revenue growth and profitability, though risks include competitive pressures and market volatility. The stock's current valuation metrics, such as a P/E of 16.19, suggest room for upside if earnings momentum continues, but investors should weigh execution risks against the bullish analyst sentiment and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
